WO2014163314A1 - 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 - Google Patents
라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 Download PDFInfo
- Publication number
- WO2014163314A1 WO2014163314A1 PCT/KR2014/002454 KR2014002454W WO2014163314A1 WO 2014163314 A1 WO2014163314 A1 WO 2014163314A1 KR 2014002454 W KR2014002454 W KR 2014002454W WO 2014163314 A1 WO2014163314 A1 WO 2014163314A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lacosamide
- pharmaceutical composition
- polymer particles
- pharmaceutically acceptable
- average particle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Definitions
- composition that facilitates the dissolution pattern of lacosamide or its pharmaceutically acceptable salts
- the present invention relates to a pharmaceutical composition in the form of a matrix comprising the active ingredient lacosamide or a pharmaceutically acceptable salt thereof. More specifically, the present invention relates to a pharmaceutical composition that is easy to control the dissolution pattern of an effective amount of lacosamide or a pharmaceutically acceptable salt thereof.
- R-2-acetamido-N-benzyl-3-methoxypripionamide of formula 1 is commonly referred to as lacosamide, and is a NMDA (N-methyl-D—aspartate) glycine site antagonist, National Institutes of Health (NIH) is a functionalized amino acid that has been identified as a promising antiepileptic drug among 24,000 molecules in its extensive search program. It is also an anticonvulsant that is being developed at the same time as an epileptic and pain relief agent.
- NASH National Institutes of Health
- Lacosamide is an active ingredient used to treat pain and the treatment of various diseases of the nervous system, including epilepsy, although its mechanism of action is not completely clear, but it can act on the sodium channels of neurons that reduce their activity and damage neurons It is thought to be involved in the restoration of (Korean Patent Publication No. 10-2013-0006438).
- US Laid-Open Patent Publication No. US 2012-0219631 discloses that it can be used as a medicine for the treatment and prevention of convulsions, migraine, fibromyalgia, osteoarthritis, neuralgia after shingles, and diabetic neuropathy with respect to lacosamide.
- US Patent No. 5,654,301 and US Patent No. 5,773,475 disclose that lacosamide can be used as a therapeutic agent for central neuropathy.
- US Patent Publication No. 2012-0219631 discloses dizziness, ataxia, vomiting, diplopia, nausea and the like as a side effect of lacosamide.
- Treatment with such lacosamide can be considered optimal when the drug reaches an effective plasma level when required, and also to reduce the incidence and severity of possible side effects (Cmax) in the highest plasma. It should be as low as possible.
- controlling the elution pattern of lacosamide or its pharmaceutically acceptable salts to reach effective plasma levels in a timely manner is very important for the treatment of various diseases using the same.
- the plasma level or the dissolution pattern of the drug required may vary, it may be necessary to adjust the dissolution pattern.
- compositions have been proposed for the active ingredient lacosamide or a pharmaceutically acceptable salt thereof to exhibit an appropriate elution pattern.
- compositions are mainly delaying the release of lacosamide, and each composition must be designed separately in order to obtain an equal dissolution pattern of the pharmaceutical composition which varies the content of the active ingredient according to the severity or symptoms of the disease. .
- the present invention is easy to control the dissolution pattern of lacosamide (lacosamide) or salts thereof, it is easy to design and manufacture the pharmaceutical composition according to the type or severity of the disease can solve the above problems.
- the present inventors have developed a pharmaceutical composition that is controlled to show a desired dissolution pattern while the dissolution pattern of the active ingredient may be equally represented in the same composition even if the content of the active ingredient included in the pharmaceutical composition is different, and the optimized therapeutic effect It was to be easy to obtain a pharmaceutical composition showing.
- an object of the present invention is to provide a pharmaceutical composition which is easy to control the dissolution pattern of the effective amount of lacosamide or a pharmaceutically acceptable salt thereof.
- the present invention also includes administering to a subject a pharmaceutical composition in the form of a matrix comprising an effective amount of lacosamide or a pharmaceutically acceptable salt thereof and ethylcelose polymer particles having an average particle diameter of 1 to 450.
- a pharmaceutical composition in the form of a matrix comprising an effective amount of lacosamide or a pharmaceutically acceptable salt thereof and ethylcelose polymer particles having an average particle diameter of 1 to 450.
- the present invention comprises the step of blending an effective amount of lacosamide or a pharmaceutically acceptable salt thereof with ethyl cellulose polymer particles having an average particle diameter of 1 to 450 ⁇ , easy dissolution pattern control pharmaceutical It is an object to provide a method for preparing a composition.
- the present invention comprises ethyl cellulose polymer particles, and meets a certain relationship between the content of lacosamide (lacosamide) and the average particle diameter of the ethyl cellulose polymer particles, the active ingredient lacosamide (lacosamide) or its Facilitates the dissolution pattern of pharmaceutically acceptable salts. Therefore, even in the case where control of the dissolution pattern or equivalent expression is required according to the type of disease, the severity and the content of the active ingredient, the separate design of the pharmaceutical composition is practically unnecessary, and thus lacosamide exhibiting a desirable therapeutic effect. Or a pharmaceutical composition of its pharmaceutically acceptable salts very easily.
- Example 1 is a schematic diagram of the dissolution of lacosamide over time of Example 1-1 1-2 and Reference Example 1-1-1-3, which are tablets containing lacosamide lOOmg. .
- Figure 2 is a schematic of the dissolution of lacosamide (lacosamide) over time of Example 2-1-2-2 and Reference Example 2-1-2-3 that is a tablet containing 200 mg of lacosamide (lacosamide) will be.
- Figure 3 is a schematic of the dissolution of lacosamide (lacosamide) over time in Examples 3-1 to 3-2 and Reference Example 3-1-3-3 that is a tablet containing 300 mg of lacosamide. will be.
- Figure 4 is a schematic of the dissolution of lacosamide (lacosamide) over time of Example 4-1-4-2 and Reference Examples 4-1 to 4-3 which is a tablet containing lacosamide 400mg will be.
- Figure 5 is an embodiment of varying the content of lacosamide (lacosamide) 1-1,2-1,3-1, 4-1 shows the constant dissolution of lacosamide (lacosamide) over time.
- Figure 6 shows the elution of lacosamide (lacosamide) with time of Comparative Example 1 1-1-1-4 with different amounts of lacosamide (lacosamide).
- FIG. 7 shows the results of PK analysis of plasma samples taken with oral administration of lacosamide, according to the time of preparation of Comparative Example 2 and Example 1-1.
- the present invention provides a matrix comprising an effective amount of lacosamide (or pharmaceutically acceptable salt thereof) and ethyl salulose polymer particles having an average particle diameter of 1 to 450 ⁇ It relates to a pharmaceutical composition in form.
- lacosamide is an amino acid derivative having analgesic and anticonvulsive action
- pharmaceutically acceptable salt of lacosamide is a free base or pharmaceutical composition of lacosamide. It can be in the form of various acceptable acid addition salts.
- the pharmaceutical composition of the present invention may further include polyvinylpyridone (Polyvinyl Pyrrol i done, PVP).
- polyvinylpyrrolidone PVP
- PVP polyvinylpyrrolidone
- the polyvinylpyridone of the present invention is not particularly limited, and examples thereof include polyvinylpyridone K-30 and polyvinylpyridone K-17.
- the same effect may be obtained by using a polymer such as hypromellose, hydroxypropyl cellulose, PEG6000, and the like as a binder.
- the pharmaceutical composition includes polymer particles of ethyl salulose, which is a water-insoluble polymer.
- Ethyl salose polymer particles are the active It may be mixed with granules containing the component, and may serve to control the dissolution of the active ingredient in the body.
- content of lacosamide may be defined as the content of lacosamide contained in a unit dosage form of a pharmaceutical composition administered at one time, for example, in one tablet.
- the content of “ lacosamide ” is It can be defined as the content of lacosamide except for the weight of the acid component added to lacosamide.
- the "average particle diameter" of the ethyl salose polymer particles may be referred to as the "weight average particle diameter" of the polymer particles, and the average particle diameter of the ethyl cellulosic polymer particles may be, for example, Measurements can be made using a particle size analyzer such as Masters izer2000 from Malvern instruments.
- the pharmaceutical composition having a matrix form of the present invention is the elution pattern of lacosamide or its salt as an active ingredient by controlling the average particle diameter of the ethyl cellulose polymer particles contained therein. It was found by experiment that it can be controlled very easily.
- each pharmaceutical composition can exhibit a different dissolution pattern only by controlling the content of lacosamide and the average particle diameter of ethyl cellulose polymer particles. .
- composition of a pharmaceutical composition comprising different amounts of active ingredients, but containing the same excipients in the same proportion to the content of the active ingredients
- composition of a pharmaceutical composition comprising different amounts of active ingredients, but containing the same excipients in the same proportion to the content of the active ingredients
- each of the pharmaceutical compositions can exhibit the same dissolution pattern. Therefore, by applying the pharmaceutical composition of the matrix form, it will be very easy to design and manufacture a pharmaceutical composition of lacosamide having the appropriate active ingredient content while showing the desired therapeutic effect depending on the type or severity of the disease. Can be.
- the content of the lacosamide (lacosamide) is 100mg
- the ethyl cellulose polymer particles may have an average particle diameter of l ⁇ 20 / m.
- the content of the lacosamide (lacosamide) is 200mg
- the ethyl cellulose polymer particles may have an average particle diameter of 10 ⁇ 80.
- the content of the lacosamide (lacosamide) is 300mg
- the ethyl cellulose polymer particles may have an average particle diameter of 40 ⁇ 180 / m.
- the content of lacosamide is 400mg
- the ethyl cellulose polymer particles may have an average particle diameter of 140 ⁇ 320imi.
- the lacosamide content of the active ingredient is 100-400 mg
- the average particle diameter of the ethyl salulose polymer particles included in the pharmaceutical composition satisfies each range, It has been found that the pharmaceutical composition may exhibit an elution pattern of the optimized active ingredient that allows once-daily administration of lacosamide.
- the dissolution pattern of lacosamide included in the pharmaceutical composition is optimized for an appropriate time. It should be possible to achieve the plasma level of the drug effective in the case of lacosamide (lacosamide) and the specific particle size of the average particle diameter of the ethyl cellulose polymer particles in the following examples to meet the lacosamide (lacosamide) It has been shown that it can exhibit an optimized dissolution pattern that allows once-daily administration of pharmaceutical compositions, including).
- the pharmaceutical composition of the present invention may be in the form of a matrix having a weight of lacosamide or a pharmaceutically acceptable salt thereof: the weight of ethyl cellulose is 1: 0.2 to 1: 0.6.
- the weight of ethyl cellulose is 1: 0.2 to 1: 0.6.
- the pharmaceutical composition of the present invention may include one or more pharmaceutically acceptable excipients, in addition to the above-described ethyl cellulose.
- the excipient means any pharmaceutically acceptable inert ingredient included in the pharmaceutical composition.
- suitable excipients that may be included in the pharmaceutical composition include 1) lactose, lactose, manny, cellulose, sorbide, and the like or any combination thereof, 2) colloidal silicon dioxide, talc, and the like. Or lubricants in any combination thereof, 3) magnesium stearate, stearic acid, hydrogenated oil, sodium stearyl fumarate or lubricants in any combination thereof, 4) colorants or preservatives.
- the types of excipients that may be included in the pharmaceutical composition are not limited to those listed above, and other various excipients may be included without limitation.
- the pharmaceutical composition provided in the matrix form may be in tablet form. It may also be formulated in dosage forms suitable for oral administration.
- lacosamide or its pharmaceutically acceptable may be a pharmaceutical composition in the form of a matrix used for the treatment or prevention of epilepsy pain, spasms, seizures, fibromyalgia, osteoarthritis, neuralgia after shingles, and diabetic neuropathy.
- the present invention may be a pharmaceutical composition in the form of a matrix administered once a day.
- the pharmaceutical composition satisfies the content of lacosamide and the average particle size range of the ethyl salose polymer particles, the pharmaceutical composition allows one-time administration of lacosamide to convulsion, In terms of therapeutic effects, such as epilepsy, the dissolution pattern of the most active ingredient can be shown.
- the present invention provides a pharmaceutical composition in the form of a matrix comprising an effective amount of lacosamide or a pharmaceutically acceptable salt thereof and ethylcelose polymer particles having an average particle diameter of 1 to 450 / ⁇ . It relates to a method for controlling the dissolution of lacosamide, comprising the step of administering to.
- control of the dissolution of the lacosamide is 1 day of lacosamide
- the present invention provides a pharmaceutical composition in the form of a matrix comprising lOOmg lacosamide or a pharmaceutically acceptable salt thereof and ethylcellose polymer particles having an average particle diameter of 1 to 20 / m. It relates to a method for controlling the dissolution of lacosamide, comprising the step of administering to.
- the present invention is 200 tng lacosamide (lacosamide) or A method of controlling the dissolution of lacosamide, comprising administering to a subject a pharmaceutical composition in the form of a matrix comprising a pharmaceutically acceptable salt thereof and ethylsalose polymer particles having an average particle diameter of 10 to 80. It is about.
- the present invention provides a pharmaceutical composition in the form of a matrix comprising 300 mg of lacosamide Oacosamide) or a pharmaceutically acceptable salt thereof and ethyl salose polymer particles having an average particle diameter of 40 to 180 ⁇ . It relates to a method of controlling the dissolution of lacosamide, including administering.
- the present invention provides a pharmaceutical composition in the form of a matrix comprising 400 nig of lacosamide Oacosamide) or a pharmaceutically acceptable salt thereof and ethyl salulose polymer particles having an average particle diameter of 140 to 320 / ⁇ . It relates to a method of controlling the dissolution of lacosamide, comprising the step of administering to.
- the present invention is easy to control the elution pattern comprising the step of blending an effective amount of lacosamide or a pharmaceutically acceptable salt thereof, and ethyl cellulose polymer particles having an average particle diameter of 1 to One method of preparing a pharmaceutical composition.
- Examples 1-1 to 1-2 and Reference Example 1-1-1-3 Preparation of a pharmaceutical composition comprising lacosamide 100 mg
- lacosamide, spray dried lactose and polyvinylpyridone (trade name: povidone K-30) were transferred to a suitable scale mixer and mixed for about 5 minutes. While mixing these powders, the mixture The granulated ethane was granulated with to prepare wet granules. The granules were then dried in a 50 ° C. tray dryer and passed through an 18-mesh sieve. The granules were combined with ethyl cellulose (trade name: Etocell 7 Std 7 (average particle size: about 310 um) or Std7FP (average particle size: about 9.7 um)), colloidal silicon dioxide (trade name: Aerosil 200), and magnesium stearate. Mixed. This mixture was compressed with a suitable tablet press to prepare 199 mg of tablets (Table 1, Figure 1).
- the average particle diameter of the ethyl cellulose polymer particles was calculated as a weight average particle diameter value measured using a particle size analyzer of Mastersizer2000, manufactured by Malvern Instruments, UK. At this time, the measurement method was based on a conventional method using a gas particle size analyzer.
- Examples 2-1 to 2-2 and Reference Examples 2-1 to 2-3 Preparation of a pharmaceutical composition comprising 200 mg of lacosamide
- lacosamide, spray dried lactose and polyvinylpyridone (trade name: povidone K-30) were transferred to a suitable scale mixer and mixed for about 5 minutes. While mixing these powders, the mixture Granulation was performed with ethanol, which was then prepared into wet granules. The granules were then dried in a 50 ° C. tray dryer and passed through an 18-mesh sieve. The granules were obtained from ethyl cellulose (trade name: Etocell 7 Std 7 (average particle size: about 310 um) or Std 7 FP (average particle size: about 9 7 um)), colloidal silicon dioxide (trade name: Aerosil 200) and stearic acid. Mixed with magnesium. This mixture was compressed with a suitable tablet press to make 398 mg of tablet.
- the average particle diameter of the ethyl cellulose polymer particles was calculated as a weight average particle diameter value measured using a particle size analyzer of Mastersizer2000, manufactured by Malvern Instruments, UK. At this time, the measurement method was based on a conventional method using a gas particle size analyzer.
- Examples 3-1 to 3-2 and Reference Examples 3-1 to 3-3 Preparation of a pharmaceutical composition comprising 300 mg of lacosamide
- lacosamide, spray dried lactose and polyvinylpyridone (trade name: povidone K-30) were transferred to a suitable scale mixer and mixed for about 5 minutes. While mixing these powders, the mixture Granulation was performed with ethanol, which was then prepared into wet granules. The granules were then dried in a tray dryer at 50 ° C. and passed through an 18-mesh sieve. The granules were combined with ethyl saloloose (trade name: Etocell 7 Std 7 (average particle size: about 310 um) or Std7FP (average particle size: about 9.7 um)), colloidal silicon dioxide (trade name: Aerosil 200) and magnesium stearate. Mixed. This mixture was compressed with a suitable tablet press to prepare 597 mg of tablet.
- the average particle diameter of the ethyl cellulose polymer particles was calculated as a weight average particle diameter value measured using a particle size analyzer of Mastersizer2000, manufactured by Malvern Instruments, UK. At this time, the measurement method was based on a conventional method using a gas particle size analyzer.
- lacosamide, spray dried lactose and polyvinylpyridone (trade name: povidone K-30) were transferred to a suitable scale mixer and mixed for about 5 minutes. While mixing these powders, the mixture The granulated ethane was granulated with to prepare wet granules. The granules were then dried in a tray dryer at 50 ° C. and passed through an 18-mesh sieve. The granules were ethyl cellulose (trade name: Etocell 7 Std 7 (average particle size: about 310um) or Std7FP (average particle size: about 9.7um)), colloidal silicon dioxide (trade name: Aerosil 200) and magnesium stearate. Mixed. This mixture was compressed with a suitable tablet press to produce 720 mg of tablet.
- the average particle diameter of the ethyl cellulose polymer particles was calculated as a weight average particle diameter value measured using a particle size analyzer of Mastersizer2000, manufactured by Malvern Instruments, UK. At this time, the measurement method was based on a conventional method using a gas particle size analyzer.
- Comparative Examples 1-1 to 1-4 Lacosamide content lOQmg, 200 mg. 300 mg. Preparation of a pharmaceutical composition comprising 400 mg
- lacosamide, hypromellose (Methocel K4M), microcrystalline cells were transferred to an appropriate scale mixer and mixed for about 10 minutes. This mixture is mixed with colloidal silicon dioxide The mixture was lubricated with magnesium stearate. Compress with a suitable tablet press to prepare comparative tablets of 180, 360, 540, 720 mg.
- Bumpat tablet 50mg (UCB Korea) was purchased and prepared.
- Example 1-1-1-2 The dissolution test of the 100 mg sustained release tablet of Reference Example 1-1-1-3 was conducted. The dissolution test tested the dissolution behavior of each tablet (unit: content%) by rotating a paddle at 50 rpm according to the Korean Pharmacopoeia's Secondary Paddle: method at 37 0 C using water 900 as the dissolution medium (Table 6, 1).
- Example 2-1-2-2 The dissolution test of the 200 mg sustained-release tablet of Reference Example 2-1-2-3 was conducted. The dissolution test tested the dissolution behavior of each tablet by rotating the paddle at 50 rpm in accordance with the Korean Pharmacopoeia Paddle Method at 37 ° C using water 900 as the dissolution medium (unit: content 3 ⁇ 4 (Table 7, Figure 2). ).
- Example 3-1-3-2 The dissolution test of the 300 mg sustained-release tablet of Reference Example 3-1-3-3 was conducted. The dissolution test tested the dissolution behavior of each tablet by rotating the paddle at 50 rpm in accordance with the KDAP method at 37 0 C using 900 m £ of water as the dissolution medium (unit: content%) (Table 8, 3).
- Example 4-1-4-2 Reference Example 4 The dissolution test of 400 mg sustained release tablets of 1 to 4-3 was performed. The dissolution test tested the dissolution behavior of each tablet (unit: content%) by rotating the paddle at 50 rpm in accordance with the Korean Pharmacopoeia Paddle Method at 37 0 C using water 900 as the dissolution medium (Table 9, Figure 9). 4).
- the active ingredient as the average particle diameter of the ethyl cellulose polymer particles are adjusted under the same composition and the same active ingredient content, It has been found that it is possible to adjust or change the elution pattern.
- the pharmaceutical compositions of Examples 4-1 to 4-2, which stratify a specific relationship between the content of lacosamide and the average particle diameter of ethyl cellulose polymer particles maintain the optimized dissolution pattern level while Elution of the active ingredient partially adjusted or changed to the desired range by controlling the average particle diameter of the polymer particles It is confirmed that the pattern can be represented.
- Example 1-1-1-4 prepared according to the methods described in Examples and Comparative Examples for the pharmaceutical compositions of Comparative Examples 1-1 to 1-4 Dissolution test was performed in a water eluate under 50 rpm conditions using the method paddle method (Table 10-11, Figures 5-6).
- the pharmaceutical compositions of Examples ll-l-4 have the same relationship between the content of lacosamide and the average particle diameter of the ethyl salulose polymer particles, even though the contents of the active ingredient lacosamide are different. It was confirmed that the dissolution patterns of the active ingredients in the composition were shown to be equal (Table 10, Fig. 5). On the other hand, referring to Table 11 and Figure 6, in the pharmaceutical compositions of Comparative Examples 1-1 to 1-4, as the content of the active ingredient is different even in the same composition, the active ingredient appears to be different from each other dissolution pattern Confirmed. Experimental Example 6: Oral Drug Dynamical Test of Lacosamide
- API i Multiple quadruple mass spectrometer
- Plasma samples stored at ⁇ 80 ° C. for treatment of plasma samples were vortexed after thawing at room temperature, centrifuged at 3600 rpm for 5 minutes, and then subdivided by 50ul. After filtering the supernatant, the supernatant was filtered and analyzed for 5ul.
- Example 7 Examples 1-1 and Comparative Example 2 and Comparative oral pharmacokinetics experiment of After the oral administration using the Mini-Pig according to Experimental Example 6 using the tablets prepared according to Example 1-1, and the tablets of Comparative Example 2 (trade name: snake pit tablet) as a control point of blood collection Before (0), after administration 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, (secondary dose), 12.5, 13, 13.5, 14, 15, 18, 24, 30, 36, PK analysis was performed using plasma samples collected at 20 times (48 (hr)), and the time point of blood collection was 0.5, 1, 1.5, 2, 3, 4, 6, PK analysis was performed using plasma samples collected 16 times in total from 8, 10, 12, 16, 24, 30, 36, and 48 (hr) (Table 12, FIG. 7).
- the average concentration of lacosamide in plasma is shown in FIG.
- the peak plasma drug concentration reaching time (Tmax) of Example 1-1 was 8hr ⁇ 3.7, and it was confirmed that the drug blood concentration was maintained for about 48 hours after administration.
- the highest plasma drug concentration (Cmax) in the control group of Comparative Example 2 was 3982 ⁇ 619 ng / mL and the highest plasma drug concentration (Cmax) in the test group (Example 1-1) was 4720 ⁇ 1190 ng / mL.
- the ratio between the group and the control group was 1.185.
- the area under the plasma concentration curve (AUC) of the control group was 114003 ⁇ 22499 ((ng / mL) * Hr) and the area under the plasma concentration curve (AUC) of the test group was 104423 ⁇ 19154 ((ng / mL) * Hr).
- AUC area under the plasma concentration curve
- Experimental Example 1-1 and Comparative Example 2 showed that they are biologically equivalent agents.
- the present invention can easily design and manufacture a pharmaceutical composition of lacosamide that exhibits the desired level of optimized dissolution pattern while maintaining the same therapeutic effect. It is confirmed that such an effect can be obtained even if the content of phosphorus lacosamide is changed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480019538.5A CN105228608B (zh) | 2013-04-02 | 2014-03-24 | 容易调节拉科酰胺或其药学上可允许的盐的溶出模式的药学组合物 |
BR112015025058-0A BR112015025058B1 (pt) | 2013-04-02 | 2014-03-24 | Composição farmacêutica do tipo matriz contendo lacosamida |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0035989 | 2013-04-02 | ||
KR1020130035989A KR101732731B1 (ko) | 2013-04-02 | 2013-04-02 | 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014163314A1 true WO2014163314A1 (ko) | 2014-10-09 |
Family
ID=51658558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/002454 WO2014163314A1 (ko) | 2013-04-02 | 2014-03-24 | 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101732731B1 (ko) |
CN (1) | CN105228608B (ko) |
BR (1) | BR112015025058B1 (ko) |
WO (1) | WO2014163314A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784134A (zh) * | 2015-04-12 | 2015-07-22 | 石家庄四药有限公司 | 一种拉科酰胺固体制剂及其制备方法 |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102544141B1 (ko) * | 2016-09-29 | 2023-06-16 | 에스케이케미칼 주식회사 | 라코사미드 서방성 제제 |
KR102083241B1 (ko) | 2018-02-14 | 2020-03-02 | 환인제약 주식회사 | 라코사미드를 함유하는 약제학적 서방성 조성물 |
CN109010301B (zh) * | 2018-09-05 | 2021-01-26 | 上海上药第一生化药业有限公司 | 一种拉考沙胺晶型ii片剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011101863A2 (en) * | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
EP2468261A1 (en) * | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
US20120219631A1 (en) * | 2009-11-03 | 2012-08-30 | Lupin Limited | Modified release formulation of lacosamide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011008298A2 (en) * | 2009-07-16 | 2011-01-20 | Nectid, Inc. | Novel axomadol dosage forms |
NZ610701A (en) | 2010-12-02 | 2015-06-26 | Ucb Pharma Gmbh | Once daily formulation of lacosamide |
-
2013
- 2013-04-02 KR KR1020130035989A patent/KR101732731B1/ko active IP Right Grant
-
2014
- 2014-03-24 BR BR112015025058-0A patent/BR112015025058B1/pt active IP Right Grant
- 2014-03-24 CN CN201480019538.5A patent/CN105228608B/zh active Active
- 2014-03-24 WO PCT/KR2014/002454 patent/WO2014163314A1/ko active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120219631A1 (en) * | 2009-11-03 | 2012-08-30 | Lupin Limited | Modified release formulation of lacosamide |
WO2011101863A2 (en) * | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Extended release pharmaceutical compositions of lacosamide |
EP2468261A1 (en) * | 2010-12-02 | 2012-06-27 | UCB Pharma GmbH | Formulation of lacosamide |
Non-Patent Citations (3)
Title |
---|
AHN, J. S. ET AL.: "Pneparation of lacosamide sustained-release tablets and their pharmacokineties in beagles and mini-pigs", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 35, no. 2, February 2014 (2014-02-01), pages 557 - 561 * |
DABBAGH, M. A. ET AL.: "Effects of polymer particle size, compaction pressure and hydrophilic polymers on drug release from matrices containing ethylcellulose", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 140, no. 1, 1996, pages 85 - 95 * |
IQBAL, Z. ET AL.: "Controlled-release naproxen using micronized ethyl cellulose by wet- granulation and solid-dispersion method", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 28, no. 2, 2002, pages 129 - 134 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104784134A (zh) * | 2015-04-12 | 2015-07-22 | 石家庄四药有限公司 | 一种拉科酰胺固体制剂及其制备方法 |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
US10987324B2 (en) | 2015-12-30 | 2021-04-27 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
Also Published As
Publication number | Publication date |
---|---|
BR112015025058A8 (pt) | 2023-01-03 |
KR101732731B1 (ko) | 2017-05-08 |
BR112015025058B1 (pt) | 2023-11-21 |
KR20140120191A (ko) | 2014-10-13 |
CN105228608B (zh) | 2019-05-28 |
CN105228608A (zh) | 2016-01-06 |
BR112015025058A2 (pt) | 2017-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100280973B1 (ko) | 방출억제성 옥시코돈 조성물 | |
AU2007201808B8 (en) | A method for alleviating signs and symptoms of spasticity | |
KR20110117216A (ko) | R-바클로펜 전구약물의 서방형 경구 투약 형태 | |
JP6444996B2 (ja) | 調節放出製剤 | |
JP2009502807A (ja) | 薬剤含有率の高い製剤および投与量形態 | |
WO2014163314A1 (ko) | 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물 | |
JP2007526277A (ja) | 経口投与を目的としたトルペリゾンの徐放性医薬組成物 | |
WO2004054574A1 (ja) | 経口固形医薬 | |
CA2647982C (en) | Solid pharmaceutical preparation containing tramadol | |
EP3013327A1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
EP3313187A1 (en) | Sustained release formulation and tablets prepared therefrom | |
WO2006123213A1 (en) | Modified release formulations of gliclazide | |
US20160228386A1 (en) | Pharmaceutical Formulation | |
EP2801350B1 (en) | Pharmaceutical Formulations of Lacosamide | |
CN108969498B (zh) | 一种盐酸替扎尼定缓释制剂及其制备工艺和用途 | |
BG64839B1 (bg) | Контролирано освобождаващи перорални състави на левосимендан | |
TW200812579A (en) | Treatment of pain | |
KR102065236B1 (ko) | 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법 | |
CN113694052B (zh) | 一种含有对乙酰氨基酚和盐酸曲马多的包衣片剂 | |
CN111481521B (zh) | 一种奥卡西平缓释制剂、制备方法及其应用 | |
US20160317662A1 (en) | Stable oral pharmaceutical composition | |
WO2023002004A1 (en) | Multiparticulate pharmaceutical composition | |
KR20120052080A (ko) | 에페리손 함유 서방정 및 이의 제조 방법 | |
CN114585362A (zh) | 治疗制剂及其用途 | |
CN103040781B (zh) | 盐酸普拉克索片剂药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480019538.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14778385 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015025058 Country of ref document: BR |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14778385 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 112015025058 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150930 |